Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
Holding ABBV?
Track your performance easily
ABBV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$136.30 - $207.32
Previous Close$171.09
Volume8.48M
Average Volume (3M)5.06M
Market Cap
$302.34B
Enterprise Value$366.17B
Total Cash (Recent Filing)$7.29B
Total Debt (Recent Filing)$71.08B
Price to Earnings (P/E)59.7
Beta0.13
Next Earnings
Jan 29, 2025EPS Estimate
$2.97Next Dividend Ex-Date
Jan 15, 2025Dividend Yield3.55%
Share Statistics
EPS (TTM)2.87
Shares Outstanding1,767,140,323
10 Day Avg. Volume7,973,261
30 Day Avg. Volume5,062,496
Standard Deviation0.07
R-Squared0.22
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)50.17
Price to Sales (P/S)5.55
Price to Cash Flow (P/CF)14.20
P/FCF Ratio13.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.59
Enterprise Value/Gross Profit10.80
Enterprise Value/Ebitda20.12
Forecast
1Y Price Target
$206.53Price Target Upside21.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
AbbVie News
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceAbbVie raises its 2024 revenue guidance to $56 billion, driven by strong performance in Skyrizi and Rinvoq.
Immunology And Inflammation GrowthContinued strong uptake of Skyrizi and Rinvoq in treating psoriatic disease and inflammatory bowel disease highlights significant growth potential beyond Humira.
Oncology And Neuroscience PerformanceSolid quarterly results in oncology and neuroscience portfolios contribute to AbbVie's robust growth, with Imbruvica sales maintaining strength.
Bears Say
Drug DevelopmentThe failure of Emraclidine trials puts a spotlight on AbbVie's challenges in the schizophrenia drug market.
Financial PerformanceThe removal of Emraclidine affected risk-adjusted 2033 sales estimates by $2.3 billion, representing approximately 3% of the total sales forecast.
Market ChallengesJuvederm is particularly challenged by macro weakness due to its higher price point.
---
Ownership Overview
0.08% Insiders
22.02% Mutual Funds
6.59% Other Institutional Investors
50.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $136.30 and its highest was $207.32 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 29, 2025 which is in 76 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2024. The company reported $3 earnings per share for the quarter, beating the consensus estimate of $2.92 by $0.08.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 3.55%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is $2.97.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $3 in its last earnings report, beating expectations of $2.92. Following the earnings report the stock price went up 6.361%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 233M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$206.53 (21.24% Upside)
$206.53 (21.24% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 94%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 323.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.96%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
ABBV Earnings Call
Q3 2024
0:00 / 0:00
---
ABBV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
ABBV Stock 12 Month Forecast
Average Price Target
$206.53
▲(21.24% Upside)
Technical Analysis
Best Analysts Covering ABBV
1 Year
1 Year Success Rate
34/39 ratings generated profit
1 Year Average Return
+21.23%
assigned a buy rating 22 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 87.18% of your transactions generating a profit, with an average return of +21.23% per trade.
---